X-ray fluorescence determination of bromine traces in pharmaceutical formulations containing sodium diclofenac.
The X-ray fluorescence spectroscopy (XRF) on solid samples is applied to the organic bromine impurities assay on pharmaceutical formulations of sodium diclofenac (DCF). A wide range of Br contents (7-1564 ppm) in the tablets is obtained, depending on manufacturer source and batch preparation. As the impurities concern only the sodium diclofenac employed, and the presence of Br might be a toxicity index arising from the synthetic procedure, the assay of each DCF batch is suggested.
Raggi
M A
MA
Department of Pharmaceutical Sciences, University of Bologna, Italy.
Lucchini
F
F
Da Re
P
P
D001966:Bromine / Q000032:analysis*; D004008:Diclofenac / Q000032:analysis*; D004340:Drug Contamination; D012015:Reference Standards; D013052:Spectrometry, X-Ray Emission
D004008:Diclofenac; D001966:Bromine